TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04091750
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction: 1mg/kg IV every 3 weeks x 4 cycles
Study: NCT04091750
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction and Maintenance: 40mg PO daily
Study: NCT03970668
Drug: Linagliptin 5 mg Oral Tablet
Normalized name: linagliptin 5 MG Oral Tablet
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients received linagliptin 5mg once daily orally plus a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
Study: NCT03970668
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
Study: NCT01824875
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03970226
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase 0: One dose of tocilizumab prior to surgery~Feasibility phase: Tocilizumab administered every 2 weeks for up to 13 cycles (approximately 1 year).
Study: NCT03666546
Drug: Lactulose crystals 20 g
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: White or almost white crystalline powder. The product will be provided in sachets to be dissolved in 250 mL water.
Study: NCT03666546
Drug: Lactulose crystals 30 g
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: White or almost white crystalline powder. The products will be provided in sachets to be dissolved in 250 mL water.
Study: NCT03666546
Drug: Lactulose liquid 20 g
Normalized name: lactulose Oral Liquid Product
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
Study: NCT03666546
Drug: Lactulose liquid 30 g
Normalized name: lactulose Oral Liquid Product
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
Study: NCT03666546
Drug: Glucose
Normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: White crystalline powder. To standardise for 30 g glucose, 33 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
Study: NCT03666546
Drug: Still water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL still water will be used. Water from the same source will be also used to dissolve investigational and control products
Study: NCT00860574
Drug: treosulfan
Normalized name: TREOSULFAN
DrugBank: Treosulfan (DB11678)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00860574
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00860574
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or PO
Study: NCT01746563
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection
Study: NCT02639819
Drug: ɛ-Aminocaproic Acid
Normalized name: Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention: intravenous ε-Aminocaproic Acid within 3 hours of symptom onset
Study: NCT04322357
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 12-month treatment period with twice weekly, low-dose prednisone (dose of 0.75 mg/kg per day).
Study: NCT04322357
Drug: Prednisone plus exercise
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice weekly prednisone for 6 months followed by twice weekly prednisone plus exercise for 6 months.
Study: NCT03033446
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 21 days after Radioembolization, 240mg of IV Nivolumab over 30 minutes will be administered every 2 weeks
Study: NCT02014649
Drug: 20 mg laninamivir octanoate
Normalized name: Octanoic acid
DrugBank: Laninamivir octanoate (DB11888)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02014649
Drug: 40 mg laninamivir octanoate
Normalized name: Octanoic acid
DrugBank: Laninamivir octanoate (DB11888)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02857777
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will self-administer intranasal esketamine as per the treatment regimen.
Study: NCT04322227
Drug: Foliglurax 10 mg (treatment A)
Normalized name: Foliglurax
DrugBank: Foliglurax (DB15292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foliglurax 10 mg, (BID) capsules, orally
Study: NCT04322227
Drug: Foliglurax 30 mg (treatment B)
Normalized name: amphotericin B 30 MG/ML
DrugBank: Foliglurax (DB15292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foliglurax 30 mg, BID capsules, orally
Study: NCT04349176
Drug: Dose
Normalized name: iDose
DrugBank: Zabedosertib (DB18767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to either 100U or 155U
Study: NCT00056589
Drug: catridecacog
Normalized name: Catridecacog
DrugBank: Catridecacog (DB09310)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Single doses of rFXIII administered intravenously (IV) to two subjects in each of the five dose levels (2, 6, 20, 50 and 75 U/kg).
Study: NCT04321980
Drug: OP-101
Normalized name: OP-101
DrugBank: Acetylcysteine zidrimer (DB16496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of OP-101 in healthy volunteers
Study: NCT02775903
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered by subcutaneous injection on Days 1 to 7 of each 4-week treatment cycle.
Study: NCT04110964
Drug: AAV-hTERT
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
Study: NCT01968395
Drug: Caspofungin 70 mg
Normalized name: caspofungin 70 mg intravenous powder for injection
DrugBank: Caspofungin (DB00520)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous use
Study: NCT02342249
Drug: VX-787 300 mg
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A oral dose of 300 mg VX-787 tablet will be administered over 5-6 days.
Study: NCT02342249
Drug: VX-787 600 mg
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A oral dose of VX-787 600 mg (formulated as 2\*300 mg tablets) will be administered over 5-6 days.
Study: NCT02342249
Drug: Oseltamivir 75 mg
Normalized name: oseltamivir 75 MG
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A oral dose of 75 mg Oseltamivir capsule will be administered over 5-6 days.
Study: NCT02923180
Drug: Enoblituzumab
Normalized name: Enoblituzumab
DrugBank: Enoblituzumab (DB15017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoblituzumab 15mg/kg IV (in the vein) weekly for 6 doses beginning 50 days prior to radical prostatectomy.
Study: NCT00221650
Drug: Peginterferon alfa2a
Normalized name: ribavirin/peginterferon alfa2a 200 mg (1 tablet)-180 mcg MISCELL COMBINATION PACKAGE (EA)
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00221650
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00161421
Drug: Leuprolide (Lupron)
Normalized name: LEUPROLIDE (LUPRON) 45MG(PED 6M)SA INJ
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg injection into muscle (once) (Day -14)
Study: NCT00161421
Drug: Dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24.5 mg load (3.5 mg x 7 capsulesDay -14 only) 0.5 mg daily (Day -13 to day -1)
Study: NCT04588532
Drug: Histamine
Normalized name: Histamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: histamine will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
Study: NCT04588532
Drug: Doxepin
Normalized name: Doxepin
DrugBank: Doxepin (DB01142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxepin cream (antihistamine) will be applied in 4 areas on the volar forearm
Study: NCT02422940
Drug: dalfampridine-ER 7.5 mg
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02422940
Drug: dalfampridine-ER 10 mg
Normalized name: dalfampridine Extended Release Oral Tablet
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03228303
Drug: Nilotinib 150 MG [Tasigna]
Normalized name: nilotinib 150 MG [Tasigna]
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib vs imatinib in patients with newly diagnosed CML-CP
Study: NCT03228303
Drug: Imatinib 400mg
Normalized name: imatinib 400 MG
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nilotinib vs imatinib in patients with newly diagnosed CML-CP
Study: NCT02518451
Drug: Valsartan 160 mg film-coated caplets (test formulation)
Normalized name: valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
Study: NCT02518451
Drug: Valsartan 160 mg film-coated caplets (reference formulation)
Normalized name: valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
Study: NCT03778359
Drug: Leuprorelin
Normalized name: Leuprorelin
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Leuprorelin.
Study: NCT03778359
Drug: Dienogest
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Dienogest.
Study: NCT04551352
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab will be administered as required for the management of severe cytokine release syndrome (CRS).
Study: NCT04551352
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: If implemented, it will be given either on D-7 or D-7 and D-6.
Study: NCT04551352
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: If implemented, it will be given as a single dose approximately 6 days prior to the first dose of RO7293583.
Study: NCT01335399
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study: NCT02843685
Drug: Drotrecogin alfa activated
Normalized name: Drotrecogin alfa activated
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04302584
Drug: norepinephrine / Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: • The drug infusion was prepared as 100 IU of AVP (Pressyn; Ferring Inc., Toronto, Ontario, Canada) in 250 ml D5W, infused at the rate of 4.5 ml/h for 0.03 IU/min and 15 mg of Norepinephrine (Arterenol; Sanofi-Aventis, Frankfurt, Germany) in 250 ml D5W infused at the rate of 10 ml/h for 10 mcg/min using infusion pump.
Study: NCT00064220
Drug: soblidotin
Normalized name: Soblidotin
DrugBank: Soblidotin (DB12677)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01335399
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study: NCT03733145
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants in the ACE inhibitors, ARBs, and Other Classes of Antihypertensive Agents who's systolic blood pressure (SBP) is less than 80% of the baseline reading is detected, will have Ang II initiated at 2 ng/kg/min through a peripheral IV. The infusion will be increased at the discretion of the clinical team based on the response of the patient until a SBP within 5% of the baseline SBP.
Study: NCT00336583
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin, 130 mg per square meter, on day 1
Study: NCT02016547
Drug: alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02732522
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02732522
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03668366
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: The patients will receive IMRT combined with S-1 concurrent chemoradiotherapy. The specific treatment description is included in arm description.
Study: NCT00303420
Drug: Alteplase push protocol
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alteplase 2 mg / lumen. Instill and wait 10 minutes, instill 0.3 ml normal saline, wait 10 minutes, instill 0.3 ml of normal saline, wait 10 minutes and aspirate.
Study: NCT01335399
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, Oral, 28 mg, once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study: NCT01335399
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, Oral, 40 mg, once daily, on Days 8 \& 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study: NCT01335399
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution, Intravenous (IV), 8 mg, Once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study: NCT03729362
Drug: Miglustat
Normalized name: Miglustat
DrugBank: Miglustat (DB00419)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants received weight-based doses 1 hour prior to cipaglucosidase alfa infusion Q2W.
Study: NCT00375375
Drug: Lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00303420
Drug: alteplase dwell arm
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alteplase 2 mg / lumen. Instill and let it dwell for 30 minutes. Assess catheter and allow to dwell for a total of 2 hours if necessary
Study: NCT01695668
Drug: Lotemax
Normalized name: Lotemax
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ophthalmic corticosteroid. It decreases inflammation of the eye
Study: NCT01695668
Drug: Restasis
Normalized name: Restasis
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restasis is an immunosuppressive agent. Cyclosporine may reduce inflammation in the eye.
Study: NCT03570632
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants randomized to metformin will receive metformin in addition to standard treatment of diabetes during pregnancy
Study: NCT06190340
Drug: TNP-2092 capsules
Normalized name: TNP-2092
DrugBank: TNP-2092 (DB16312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration orally.
Study: NCT02103725
Drug: pimecrolimus 10 mg/g cream
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01631656
Drug: Azelaic acid
Normalized name: Azelaic Acid
DrugBank: Azelaic acid (DB00548)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15% gel on half the face, twice daily, 6 weeks
Study: NCT02626481
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: patients treated with Daratumumab (16 mg/kg) and Dexamethasone (40 or 20 mg regarding age of patient)
Study: NCT02626481
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients treated with Dexamethasone (40 or 20 mg regarding age of patient)
Study: NCT04573751
Drug: Verapamil
Normalized name: Verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard therapy plus verapamil as follows: verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
Study: NCT00791336
Drug: Nelfinavir
Normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1250 mg twice daily starting for approximately 6.5 weeks.
Study: NCT01291199
Drug: vardenafil
Normalized name: Vardenafil
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg p.o. bid for 6 weeks
Study: NCT03241745
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 480 mg IV once every 4 weeks
Study: NCT02464059
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks in individuals with reduced vitamin D levels.
Study: NCT03206073
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500 mg of durvalumab via intravenous (IV) infusion on Day 1 of each cycle until patients meet off treatment criteria
Study: NCT03206073
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of tremelimumab via intravenous (IV) infusion on Day 1 of cycle 1
Study: NCT00490737
Drug: daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6mg/kg, i.v. infusion over 30 minutes; every 48 hours for a total of 3 doses
Study: NCT01074307
Drug: Low Dose Bisoprolol
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bisoprolol tablet (Concor) will be administered orally at a starting dose of 1.25 milligram (mg) once daily for 2 weeks. The dose will be further escalated from 1.25 mg to 2.5 mg once daily after 2 weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
Study: NCT03748641
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive niraparib 200 mg capsules or tablets once daily.
Study: NCT03748641
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive AA 1000 mg tablets once daily.
Study: NCT03748641
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive prednisone 10 mg tablets daily.
Study: NCT03748641
Drug: New Formulation of Niraparib and Abiraterone Acetate (AA)
Normalized name: niraparib and abiraterone
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets once daily.
Study: NCT04179747
Drug: Sildenafil Citrate 50Mg Tab
Normalized name: SILDENAFIL CITRATE 50MG TAB
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The participants in control group arm received Sildenafil Citrate 50mg tablet on demand for a period of maximum 3 months.
Study: NCT00616434
Drug: BG9418 (Interferon beta-1a)
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Avonex IM injection, self-administered per protocol
Study: NCT01074307
Drug: High Dose Bisoprolol
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bisoprolol tablet (Concor) will be administered orally at a starting dose of 3.75 mg once daily for 2 weeks. The dose will be subsequently increased to 5 mg, 7.5 mg, or 10 mg once daily every two weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
Study: NCT01522976
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC or IV
Study: NCT01522976
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01522976
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03593434
Drug: hyperpolarized Xenon gas
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This present study will utilize existing study visits for the NHLBI study, with patients opting-in to have all of the procedures performed twice, with an intervening ACT, during one their study visits.